First trial participant received the dose (ANSA) The US pharmaceutical company Moderna has begun testing for a specific vaccine booster to combat the Omicron variant. According to a note from the group, the first participant in the trial, explained Moderna, received the dose. The company promises to share the results and data with health authorities to facilitate the task of identifying the best strategies for recalls against Covid 19.
The US pharmaceutical company Moderna has begun testing for a specific vaccine booster to combat the Omicron variant.
According to a note from the group, the first participant in the trial, explained Moderna, received the dose.
The company promises to share the results and data with health authorities to facilitate the task of identifying the best strategies for recalls against Covid 19.